Non mi faccio problemi sui vaccini.
E' che se lo scopo e' salvare i novax, allora grazie no grazie.
Ovviamente la mia e' una specie di boutade, ma solo fino ad un certo punto.
E cmq la situazione pare destinata a complicarsi... purtroppo.
Se ti può essere utile, qui c'è un documento FDA che analizza la questione sicurezza e costo/beneficio nella fascia 5-12 anni di età
TFP Link :: https://www.fda.gov/media/153409/downloadUn estratto:
"Overall Risk-Benefit Conclusions
COVID-19 continues to be a serious and potentially fatal or life-threatening infection for children and there is a significant unmet medical need in the 5 to <12 years of age
population.
Two primary doses of the 10 µg BNT162b2 vaccine given 3 weeks apart in 5 to <12 years of age have shown a favorable safety and tolerability profile, robust immune responses against all variants of concern and high VE against symptomatic COVID-19 in a period where the
delta variant was predominant.
The number of participants in the current clinical development program is too small to detect any potential risks of myocarditis associated with vaccination. Long-term safety of COVID-19 vaccine in participants 5 to <12 years of age will be studied in
5 post-authorization safety studies, including a 5-year follow-up study to evaluate long term sequelae of post-vaccination myocarditis/pericarditis.
Israelisafety surveillance databases suggest that incidence rates of rare post-vaccination myocarditis peaks in individuals 16 to 19 years of age males and declines in adolescents 12 to 15 years of age. In addition, the dose for children 5 to <12 years of age is 1/3 of the
dose given to older vaccinees (10 µg vs. 30 µg). Based on this information, it is reasonable to predict that post-vaccine myocarditis rates are likely to be even lower in 5 to <12 years of age than those observed in adolescents 12 to 15 years of age.
Given post-authorization experience and assuming 90% efficacy as shown in the descriptive clinical study, the estimated number of COVID-19 cases and associated hospitalizations prevented over 120 days per million of fully vaccinated children 5 to <12 years of age is
~33,600 and 170, respectively. In contrast, the number of post-vaccination myocarditis cases
(including myocarditis, pericarditis, and myopericarditis) expected in the same period of time per million second doses is 21 (assuming that children 5 to <12 years of age experience the same rates of post-vaccination myocarditis/pericarditis as adolescents 12 to 15 years of age in the US) (Section 4). We therefore may expect substantially fewer post-vaccination
myocarditis cases among 5 to <12 of age males and females than COVID-19-associated hospitalizations given current age-specific COVID-19 cases and hospitalization rate estimates. Prevention of potential long-term sequelae of COVID-19 illness as well as other societal impacts would further increase the public health benefit of vaccination.
Given all the above, the benefits of the Pfizer-BioNTech COVID-19 Vaccine to prevent COVID-19 given as a two-dose, 10 µg dose level, primary series in children 5 to <12 years"